Featured News

ZED1227, an experimental drug was found to be able to prevent intestinal damage in a preliminary trial of 163 adults with celiac disease.

As members of the Consumers United for Evidence-based Healthcare, the Celiac Disease Foundation invites you to join us at the Virtual 2021 CUE Annual Membership Meeting: Bridging the Gap between Evidence and Action: Implications for Health Equity.

The overall prevalence of celiac disease was found to be 1.6% - a much greater percentage than the 1% that researchers have been approximating for years.

A recent study published in JAMA Network, using two decades worth of dietary data, concluded that gluten consumption in people without celiac disease did not impair cognitive function.

Each year, we look forward to May Celiac Awareness Month for the chance to celebrate our community’s tireless work.

The CeDLara Study is for adults who have been diagnosed with celiac disease and are still experiencing symptoms despite following a gluten-free diet.

Latiglutenase is a dual enzyme investigational product designed to break down gluten in the stomach. Learn more about the trial and what this means for celiac disease patients.

Ukko, a startup focused on eradicating food allergies, intolerances, and sensitivities, has reached a promising stage in its effort to develop a gluten specifically designed for people with celiac disease.

We are determined to use every resource at our disposal, including strategic funding of research and advocacy, to help discover and bring to the celiac disease patient community therapeutic alternatives to the gluten-free diet.

The Celiac Disease Foundation is proud to announce its sponsorship of the April 17th University of Chicago’s Celiac Disease & The Continuum of Care Virtual CME Symposium.